Validation of REM Score to Predict Endometrial Cancer in Patients with Ultrasound Endometrial Abnormalities: Results of a New Independent Dataset

Overview

Journal Med Oncol

Publisher Springer

Specialty Oncology

Date 2017 Apr 9

PMID 28389908

Citations 3

Authors

Francesco Plotti

Stella Capriglione

Corrado Terranova

Roberto Montera

Giuseppe Scaletta

Salvatore Lopez

Daniela Luvero

Antonelli Gianina

Alessia Aloisi

Pierluigi Benedetti Panici

Roberto Angioli

Affiliations

Soon will be listed here.

Abstract

The risk of endometrial malignancy (REM) score is a model formulated in a previous single-center validation study, which has been shown to predict endometrial cancer in women with ultrasound endometrial abnormalities based on multiple features (clinical, ultrasound and laboratorial). The purpose of this study was to validate the performance of REM score in an external validation setting. A population-based database with patients, who underwent elective hysteroscopy for ultrasound endometrial abnormalities between 2013 and 2016 at Department of Obstetrics and Gynecology of Campus Bio-medico of Rome, was used. Starting from January 2013 to June 2016, 330 patients were enrolled for hysteroscopy. Thirty-two patients were excluded due to Asherman syndrome or cervical stenosis. Therefore, a total of 298 patients were considered for the analysis. Based on pathologic examination, 102 patients were found to have endometrial cancer, and 196 had benign endometrial disease. Using the predefined cutoff of 0.3185, identified in the previous publication, in this independent cohort of patients we correctly classified 93/102 patients with endometrial cancer and 187/196 with benign disease, reporting an overall sensitivity and specificity of 93.9 and 95.4% (PPV = 0.91, NPV = 0.95), respectively. REM score showed a high positive predictive value for endometrial cancer prediction. However, before REM score can be applied in daily clinical practice, data from randomized controlled trials are needed.

Citing Articles

HE4 as a Biomarker for Endometrial Cancer.

Behrouzi R, Barr C, Crosbie E Cancers (Basel). 2021; 13(19).

PMID: 34638250 PMC: 8507549. DOI: 10.3390/cancers13194764.

Establishing patterns on hysteroscopy in abnormal uterine bleeding (AUB).

Pandey D, Kunamneni S, Reddy Inukollu P, Su H Gynecol Minim Invasive Ther. 2018; 6(4):178-182.

PMID: 30254909 PMC: 6135195. DOI: 10.1016/j.gmit.2017.08.001.

Ovarian cancer recurrence and early detection: may HE4 play a key role in this open challenge? A systematic review of literature.

Capriglione S, Luvero D, Plotti F, Terranova C, Montera R, Scaletta G Med Oncol. 2017; 34(9):164.

PMID: 28825178 DOI: 10.1007/s12032-017-1026-y.

References

Jacobs I, Gentry-Maharaj A, Burnell M, Manchanda R, Singh N, Sharma A . Sensitivity of transvaginal ultrasound screening for endometrial cancer in postmenopausal women: a case-control study within the UKCTOCS cohort. Lancet Oncol. 2010; 12(1):38-48. DOI: 10.1016/S1470-2045(10)70268-0. View

Capriglione S, Plotti F, Miranda A, Lopez S, Scaletta G, Moncelli M . Further insight into prognostic factors in endometrial cancer: the new serum biomarker HE4. Expert Rev Anticancer Ther. 2016; 17(1):9-18. DOI: 10.1080/14737140.2017.1266263. View

Bignotti E, Ragnoli M, Zanotti L, Calza S, Falchetti M, Lonardi S . Diagnostic and prognostic impact of serum HE4 detection in endometrial carcinoma patients. Br J Cancer. 2011; 104(9):1418-25. PMC: 3101927. DOI: 10.1038/bjc.2011.109. View

Plotti F, Capriglione S, Terranova C, Montera R, Aloisi A, Damiani P . Does HE4 have a role as biomarker in the recurrence of ovarian cancer?. Tumour Biol. 2012; 33(6):2117-23. DOI: 10.1007/s13277-012-0471-7. View

Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun M . Cancer statistics, 2009. CA Cancer J Clin. 2009; 59(4):225-49. DOI: 10.3322/caac.20006. View

Kalogera E, Scholler N, Powless C, Weaver A, Drapkin R, Li J . Correlation of serum HE4 with tumor size and myometrial invasion in endometrial cancer. Gynecol Oncol. 2011; 124(2):270-5. PMC: 3913473. DOI: 10.1016/j.ygyno.2011.10.025. View

Li J, Dowdy S, Tipton T, Podratz K, Lu W, Xie X . HE4 as a biomarker for ovarian and endometrial cancer management. Expert Rev Mol Diagn. 2009; 9(6):555-66. PMC: 3273415. DOI: 10.1586/erm.09.39. View

Smith-Bindman R, Weiss E, Feldstein V . How thick is too thick? When endometrial thickness should prompt biopsy in postmenopausal women without vaginal bleeding. Ultrasound Obstet Gynecol. 2004; 24(5):558-65. DOI: 10.1002/uog.1704. View

Angioli R, Plotti F, Capriglione S, Aloisi A, Montera R, Luvero D . Can the preoperative HE4 level predict optimal cytoreduction in patients with advanced ovarian carcinoma?. Gynecol Oncol. 2012; 128(3):579-83. DOI: 10.1016/j.ygyno.2012.11.040. View

10.

Angioli R, Capriglione S, Aloisi A, Ricciardi R, Scaletta G, Lopez S . A Predictive Score for Secondary Cytoreductive Surgery in Recurrent Ovarian Cancer (SeC-Score): A Single-Centre, Controlled Study for Preoperative Patient Selection. Ann Surg Oncol. 2015; 22(13):4217-23. DOI: 10.1245/s10434-015-4534-z. View

11.

Brennan D, Hackethal A, Mann K, Mutz-Dehbalaie I, Fiegl H, Marth C . Serum HE4 detects recurrent endometrial cancer in patients undergoing routine clinical surveillance. BMC Cancer. 2015; 15:33. PMC: 4342867. DOI: 10.1186/s12885-015-1028-0. View

12.

Angioli R, Plotti F, Capriglione S, Scaletta G, Dugo N, Aloisi A . Preoperative local staging of endometrial cancer: the challenge of imaging techniques and serum biomarkers. Arch Gynecol Obstet. 2016; 294(6):1291-1298. DOI: 10.1007/s00404-016-4181-z. View

13.

Renehan A, Tyson M, Egger M, Heller R, Zwahlen M . Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet. 2008; 371(9612):569-78. DOI: 10.1016/S0140-6736(08)60269-X. View

14.

Omer B, Genc S, Takmaz O, Dirican A, Kusku-Kiraz Z, Berkman S . The diagnostic role of human epididymis protein 4 and serum amyloid-A in early-stage endometrial cancer patients. Tumour Biol. 2013; 34(5):2645-50. DOI: 10.1007/s13277-013-0814-z. View

15.

Abu-Rustum N, Zhou Q, Gomez J, Alektiar K, Hensley M, Soslow R . A nomogram for predicting overall survival of women with endometrial cancer following primary therapy: toward improving individualized cancer care. Gynecol Oncol. 2009; 116(3):399-403. PMC: 3870336. DOI: 10.1016/j.ygyno.2009.11.027. View

16.

Awtrey C . Nomograms for predicting endometrial cancer recurrence. Gynecol Oncol. 2012; 125(3):513-4. DOI: 10.1016/j.ygyno.2012.04.035. View

17.

Braicu E, Fotopoulou C, Van Gorp T, Richter R, Chekerov R, Hall C . Preoperative HE4 expression in plasma predicts surgical outcome in primary ovarian cancer patients: results from the OVCAD study. Gynecol Oncol. 2012; 128(2):245-51. DOI: 10.1016/j.ygyno.2012.11.023. View

18.

Angioli R, Capriglione S, Aloisi A, Luvero D, Cafa E, Dugo N . REM (risk of endometrial malignancy): a proposal for a new scoring system to evaluate risk of endometrial malignancy. Clin Cancer Res. 2013; 19(20):5733-9. DOI: 10.1158/1078-0432.CCR-13-1376. View

19.

Angioli R, Miranda A, Aloisi A, Montera R, Capriglione S, De Cicco Nardone C . A critical review on HE4 performance in endometrial cancer: where are we now?. Tumour Biol. 2013; 35(2):881-7. DOI: 10.1007/s13277-013-1190-4. View

20.

Plebani M . HE4 in gynecological cancers: report of a European investigators and experts meeting. Clin Chem Lab Med. 2012; 50(12):2127-36. DOI: 10.1515/cclm-2012-0373. View